Financials
- Fiscal year
- 2025
- Total assets
- €197,179
- Loss
- -€10,092
- Solvency
- 54.3%
Total assets▼ 13.3%
Net result
20182025
PARACELSUS PHARMA PROJECTS
ActiveSummary
PARACELSUS PHARMA PROJECTS has been active since 2001 and the Belgian State Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €107,010 and a net result of -€10,092. Equity is shrinking by ~5.4% per year across the filed fiscal years. Its solvency ranks better than 67% of 21938 sector peers (fiscal year 2025). The computed 12-month bankruptcy probability is 0.5% (low).
Overview
Activity
Retail sale of pharmaceutical products
NACE 47730Warehousing and support activities for transportation NACE 52310
1 site
Size
€197,179total assets 2025
- Equity
- €107,010
- Loss
- -€10,092
Turnover not published (abridged schema)
Structure
Accounts 2 d early1 of 3 deeds read
Why 81- Sector Retail trade (NACE 47)- Loss of €10,092, the second in a row (FY 2025)- Liquidity: current ratio 0.03, cash €1,284, halved+ Founded in 2001Show the evidence
Checked score
Score 2025
81
/ 100
Excellent
Probability in this band: under 0.55%
Better than 41% of its sector peers (NACE 47, micro)
Performance against the sector, not lower risk
Financial strength · tick = 2024
Average
Solvency
79+3
equity 54.3% of total assets
Liquidity
28-5
short-term debt 45.7% · cash 0.7%
Profitability
62-5
return on assets -5.1%
Bankruptcy probability, 12 months
0.5%
Low
0%0.5%1.5%4%10%≥ 25%
About 5 in 1,000 comparable companies go bankrupt within 12 months (an estimate).
Last 24 months
11-2024: 0.4%
12-2024: 0.4%● 0.0% vs 11-2024
01-2025: 0.4%▼ -1.3% vs 12-2024
02-2025: 0.4%● 0.0% vs 01-2025
03-2025: 0.4%● 0.0% vs 02-2025
04-2025: 0.4%▲ +8.2% vs 03-2025
05-2025: 0.4%▼ -2.7% vs 04-2025
06-2025: 0.4%▼ -3.5% vs 05-2025
07-2025: 0.3%▼ -17.6% vs 06-2025
08-2025: 0.3%● 0.0% vs 07-2025
09-2025: 0.3%● 0.0% vs 08-2025
10-2025: 0.3%● 0.0% vs 09-2025
11-2025: 0.3%● 0.0% vs 10-2025
12-2025: 0.3%● 0.0% vs 11-2025
01-2026: 0.3%▼ -0.9% vs 12-2025lowest value
02-2026: 0.3%● 0.0% vs 01-2026lowest value
03-2026: 0.3%● 0.0% vs 02-2026lowest value
04-2026: 0.3%▲ +7.9% vs 03-2026
05-2026: 0.3%▼ -2.1% vs 04-2026
06-2026: 0.3%▼ -3.6% vs 05-2026
07-2026: 0.3%▲ +6.9% vs 06-2026
08-2026: 0.5%▲ +50.7% vs 07-2026
09-2026: 0.5%● 0.0% vs 08-2026
10-2026: 0.5%▲ +0.8% vs 09-2026highest value
- Founded in 2001 lowers the probability for this profile
- Sector Retail trade (NACE 47) raises the probability
- Loss of €10,092, the second in a row (FY 2025) raises the probability
- Liquidity: current ratio 0.03, cash €1,284, halved raises the probability
Credit up to €8,000 at 30 days acceptable
Liquidity short (current ratio 0.03 against 0.14 in 2024; short-term debt: 45.7% and cash: 0.7% of total assets), and 45.7% of the assets are financed with debt.
How it is calculated
The band comes from the bankruptcy probability on a scale of 0 to 100: every 10 points more double the odds of getting through the year without bankruptcy.
| 75-100 | Excellent | under 0.55% |
| 60-74 | Healthy | 0.55% to 1.5% |
| 45-59 | Fair | 1.5% to 4.2% |
| 25-44 | Weak | 4.2% to 15.0% |
| 0-24 | Critical | over 15.0% |
Place inside the band: half the bankruptcy probability, half how the company does against its sector peers (NACE 47, micro). Better than this share of them on solvency 68%, liquidity 26%, profitability 44%, growth against the median 27%. That is performance, not lower risk; the band itself always comes from the probability.
Bankruptcy probability: model pd-v3.202610021621, computed on 03-10-2026. The model learns from Belgian bankruptcies and reads the registers, the annual accounts and the gazette.
Ceilings: negative or zero equity, a heavy loss, a special KBO legal situation and a missing filing 59 (two missing 44), an ongoing judicial reorganisation or an ending 24. Financial strength does not count in the score.
Credit check for your own amount and term
Show the recommended maximum : and see how the verdict changes with amount, term and advance.
Signals
Six signals. The signal on the left, the evidence on the right.
−lowers risk+raises risk○neutral
raises risk · Persistent losses
Two consecutive loss-making years (2024 and 2025); equity is also lower. May indicate structural pressure on profitability.
NBB · annual accounts 2025Net result per financial year
1819202122232425
2018 to 2025 · latest year -€10,092
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 29-07-2026, 2 days ahead of the deadline.
NBB · 10 filingsDeviation from the deadline
2025
2 d early
2024
48 d early
2023
1 d early
2022
41 d early
2021
25 d early
2020
33 d early
2019
14 d early
← before the deadline
after the deadline →
tick = median of all Belgian filingsring = median in the sector
This company filed its last 7 accounts on average 23 days before the deadline; the sector median for financial year 2024 is on the deadline day, and 47% of the sector filed late.
Checked, nothing found (2)
neutral · The next deadline is still running
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today. Usually files around 6 July (5 of the last 5 filed years within 30 days of that day).
Companies Code · seven monthsPosition in the running window
04-10-2026 today31-12-2026 close31-07-2027 deadline
- Annual accounts filedfiscal year 2025 · micro…
- Resignation: Patrick Laseure (manager)State Gazette act
- Annual accounts filedfiscal year 2024 · micro…
Key points
- Risk: 8 loss-making years in a rowloss fiscal year 2025 -€10,092 View
- Caution: Among the weakest 18% on net resultsector median €5,059 · 21,916 companies -€10,092 View
- Positive: Always filed on timeaccounts within the deadline every year 8 years View
- A director leftlatest change 01-05-2026 · 0 in office 1 left View
By topic
Timeline
- Events
- 12
- Since
- 2017
- Next accounts
- by 31-07-2027
- 29-07-2026Annual accounts filed
- 22-05-2026Resignation: Patrick Laseure (manager)
- 13-06-2025Annual accounts filed
Company details
- Sites
- 1
- Legal form
- Private limited company (pre-2019)
- Activity
- Retail sale of pharmaceutical productsNACE 47730
- Founded
- 01-08-2001
- Year ends
- 31-12
- Peppol
- Reachable for e-invoices
Go further with this company
How much credit can you give this customer, and on what term?Credit check What should you check before you do business with this company?Supplier due diligence Can you accept this company as a client under the anti-money-laundering law?AML client file Which of your other customers can you e-invoice via Peppol?Peppol check How does this company compare with its sector?Sector benchmark What changed in the latest annual accounts?What changed
Your own company? See how customers, suppliers and banks see it and what to improve first.
Investigating this company? Keep it with today's facts in a case file.